South and Central America Hemostasis Analyzers Market

South and Central America hemostasis analyzers market in South and Central America is expected to grow from US$ 212.02 million in 2021 to US$ 381.49 million by 2028; it is estimated to grow at a CAGR of 8.8% from 2021 to 2028.  

Hemostasis analyzers provide a quick and easy measurement of blood platelet levels. A coagulation test could help detect and prevent blood clots that could cause a heart attack. A coagulation analyzer can measure the speed of the coagulation pathway and the amounts of thrombolin and thromboplastin in less than a few minutes. Cardiovascular diseases (CVDs) are likely to remain the most significant cause of morbidity and mortality worldwide. The CVDs are disorders of the heart and blood vessels and include cerebrovascular disease, coronary heart disease, rheumatic heart disease, and other conditions. Some lifestyle-related issues that lead to cardiovascular diseases and difficulties are tobacco use, unhealthy diet, and physical inactivity. They increase the risk of heart attacks and strokes. Other risk factors for cardiovascular diseases are high blood pressure, diabetes, and increased cholesterol levels. According to the WHO, cardiovascular diseases are the number one cause of death. Moreover, the growing awareness regarding the benefits of hemostasis analyzers, such as reducing conduction in atrioventricular nodes, in controlling atrial fibrillation patients' heart rate is adding to their demands, aiding the market.

The outbreak of COVID–19 has stringently affected medical services in the South and Central America region. Also, the nations are famous for medical tourism, which is also influenced by the pandemic. The second wave of COVID19 has affected Brazil, Argentina, Uruguay, Chile, Peru, and Colombia. It is anticipated that the region will likely impose a lockdown due to the emerging risk of the new COVID19 variant omicron, which is expected to increase the rate of infection, which will eventually hamper the healthcare industry in the area. Brazil, Argentina, Uruguay, Chile, Peru, Colombia is concerned by the third wave of COVID19 infection. Amongst which Brazil has registered the majority of the deaths. It is anticipated that the region will likely force a second lockdown, which will ultimately hamper the healthcare industry in the area.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the South and Central America hemostasis analyzers market. The South and Central America hemostasis analyzers market is expected to grow at a good CAGR during the forecast period.

 South and Central America Hemostasis Analyzers Market Revenue and Forecast to 2028(US$ Million)

South and Central America Hemostasis Analyzers Market Segmentation

By Product Type

• Laboratory Analyzer
  • Automated Systems
  • Semi-Automated Systems
  • Manual Systems
• Point-of-Care Testing Systems

By Test

• Activated Partial Thromboplastin Time
• D-Dimer Test
• Fibrinogen Test
• Prothrombin Time (PT) Test
• Others

By End User

• Hospitals/ Clinics
• Independent Diagnostic Laboratories
• Home Care Setting
• Others

By Country

• South and Central America
  •  Brazil
  • Argentina
  • Rest of South and Central America

Companies Mentioned -

•  Siemens Healthineers AG
• Abbott 
•  Sysmex Corporation
• Nihon Kohden Corporation
• THERMO FISHER SCIENTIFIC INC.
• HOFFMANN-LA ROCHE LTD.
• Instrumentation Laboratory Company